Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016', provides in depth analysis on Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted pipeline therapeutics. The report provides comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - The report reviews Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics and enlists all their major and minor projects - The report assesses Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) Overview 6 Therapeutics Development 7 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Products under Development by Stage of Development 7 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Products under Development by Therapy Area 8 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Products under Development by Indication 9 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Products under Development by Companies 13 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Companies Involved in Therapeutics Development 20 APAvadis Biotechnologies Srl 20 Quantum Genomics SA 21 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Drug Profiles 22 Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 QGC-001 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 QGC-006 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 QGC-011 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 QGC-101 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Featured News & Press Releases 29 May 17, 2016: Quantum Genomics granted two new U.S. patents covering lead product QGC001 29 Feb 03, 2016: Quantum Genomics Expands U.S. Presence to Advance Its Development Programs for Cardiovascular Diseases 29 Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 31 Sep 22, 2015: Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015 31 Mar 03, 2015: First patients recruited for Phase IIa trial of drug candidate QGC001 32 Jan 12, 2015: Quantum Genomics at J.P. Morgan 34th annual healthcare conference 33 Dec 11, 2014: Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure 33 Nov 17, 2014: Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension 33 Jun 18, 2014: Quantum Genomics disclosed the final results of phase I clinical trials for QGC001 during the joint Meeting of the European and International Societies of Hypertension in Athens 34 Jan 10, 2014: ANR provides a grant of € 1 million for the implementation of a research program with the QGC001 35 Dec 06, 2013: Quantum Genomics announces first results of clinical phase I studies conducted with product QGC001 35 Oct 18, 2012: Quantum Genomics Successfully Completes Phase Ia Study Of QGC001 For Treatment Of Hypertension 35 Apr 13, 2012: Quantum Genomics Announces Initiation Of First-In-Human Clinical Study With QGC001 35 Jan 05, 2012: Quantum Genomics Receives Approval For First Clinical Trial In Human Of QGC001 From Patients Protection Committee In France 36 Apr 01, 2011: Quantum Announces Positive Scientific Results For QGC001 In Hypertension 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Comparative Analysis by Unknown Stage Development, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by APAvadis Biotechnologies Srl, H2 2016 20 Pipeline by Quantum Genomics SA, H2 2016 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
